There is some short covering going on but I doubt that is the real reason for this run-up. RGEN has been undervalued for a long time. Mr market just figured that out.
Try to find another biotech company with absolutely no debt, loads of money in the bank, increasing revenue, exceptional management, promising products in the pipeline and projected to earn over 60 cents a share this year - selling for $8.
Such companies do not exist and RGEN might not be at $8 for long.
Hello Mplains - Wow - have to believe with over 1M shares this is short covering so we could go up another 2-3 days - the article may have helped just a little. So finally some share price appreciation after 7 years of misery! ha! AND with an acquisition we can sustain growth for years to come - to me our new core "bioprocessing" is golden and no more ups and down down of fda nonsense ha!
Congrats to all!